Dr. Adam Brufsky opens the discussion by introducing the evolving treatment landscape for patients with HR-positive/HER2-negative metastatic breast cancer.
Optimizing Treatment Strategies in HR-Positive/HER2-Negative Breast Cancer: Sequencing, Targeted Therapy, and Emerging Endocrine Approaches
Dr. Adam Brufsky leads a discussion on the evolving role of triplet therapy in HR-positive/HER2-negative metastatic breast cancer, focusing on the clinical implications of the INAVO-120 study and how its findings may influence treatment selection.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Full Approval to Afami-Cel for Advanced Synovial Sarcoma
2
Dose-Modified, Fixed-Duration Ibrutinib Plus Venetoclax Meets ORR End Point in Untreated CLL
3
Breaking Treatment Barriers: Therapy for Advanced (Metastatic) EGFR-Mutated Non-Small Cell Lung Cancer After Targeted Therapy and Chemotherapy
4
Venetoclax/Ibrutinib Clears Resistance Mutations in BTK Inhibitor–Resistant CLL
5